신장질환 치료제 시장 규모, 점유율 및 성장 분석 : 질환별, 약제 클래스별, 유통경로별, 지역별 - 업계 예측(2026-2033년)

Global Nephrology Drugs Market size was valued at USD 22.52 Billion in 2024 and is poised to grow from USD 24.19 Billion in 2025 to USD 42.85 Billion by 2033, growing at a CAGR of 7.42% during the forecast period (2026-2033).

The global nephrology drugs market is primarily propelled by the increasing prevalence of chronic kidney disease, heightening the need for therapies that mitigate disease progression and manage associated complications, ultimately lowering hospitalization expenses. This market encompasses treatments for chronic kidney disease, dialysis complications, and acute kidney injury, highlighting the significant burden renal diseases impose on healthcare systems. The sector has evolved from traditional dialysis support to innovative disease-modifying therapies, such as SGLT2 inhibitors and mineralocorticoid receptor antagonists, which have transformed treatment practices and attracted investment from biotech firms. Regulatory approvals and expanded indications play a crucial role in accelerating market growth by facilitating wider adoption of effective therapies, leading to improved patient outcomes and reduced healthcare costs, further supporting the advancement of precision medicine and novel treatment approaches.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nephrology Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nephrology Drugs Market Segments Analysis

Global nephrology drugs market is segmented by disease indication, drug class, distribution and region. Based on disease indication, the market is segmented into Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Acute Kidney Injury, IgA Nephropathy and Diabetic Nephropathy. Based on drug class, the market is segmented into Erythropoiesis-Stimulating Agents (ESAs), SGLT2 Inhibitors, ACE Inhibitors and ARBs. Based on distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nephrology Drugs Market

The rising prevalence of chronic kidney disease is creating an urgent demand for effective diagnostic monitoring and long-term pharmaceutical treatments, positioning nephrology-related medications at the forefront of healthcare priorities. This surge in patient numbers presents pharmaceutical companies with significant opportunities to broaden their development pipelines to introduce innovative therapies. Additionally, it encourages payers to establish coverage plans for these new treatments while fostering ongoing research and development of advanced formulations and delivery systems. Together, these factors enhance the adoption of nephrology drugs, emphasizing the importance of robust clinical evidence and optimizing healthcare resource allocation, thereby driving substantial growth in the global nephrology drugs market.

Restraints in the Global Nephrology Drugs Market

The high cost associated with new nephrology drugs, along with limited reimbursement in various healthcare environments, presents significant barriers to patient access and provider adoption. When patients are required to bear most or all of the medication costs, healthcare professionals often opt for older or less expensive alternatives, resulting in lower market uptake. Additionally, stringent utilization guidelines imposed by insurance payors and health systems can prolong the process of getting these drugs approved for formularies and restrict patients' ability to maintain ongoing treatment. Such challenges severely hinder the growth of commercial opportunities and limit market penetration for nephrology drugs.

Market Trends of the Global Nephrology Drugs Market

The global nephrology drugs market is experiencing a significant shift towards precision medicine, characterized by the development of personalized treatment strategies. By leveraging genetic insights and disease manifestation, drug developers are creating tailored therapies that cater to individual patient needs. The integration of biomarkers facilitates the identification of patient sub-populations, enhancing the potential for positive clinical outcomes and optimizing trial efficiency. Collaboration among pharmaceutical companies, diagnostic developers, and healthcare providers is increasingly prioritized, leading to the design of medications that align with patient biology. This trend is further fueled by heightened investments in translational research and real-world evidence initiatives aimed at refining treatment protocols for chronic kidney disease management.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Nephrology Drugs Market Size by Disease Indication & CAGR (2026-2033)

• Market Overview
• Chronic Kidney Disease (CKD)
• End Stage Renal Disease (ESRD)
• Acute Kidney Injury
• IgA Nephropathy
• Diabetic Nephropathy

Global Nephrology Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Erythropoiesis-Stimulating Agents (ESAs)
• SGLT2 Inhibitors
• ACE Inhibitors
• ARBs

Global Nephrology Drugs Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online

Global Nephrology Drugs Market Size & CAGR (2026-2033)

• North America (Disease Indication, Drug Class, Distribution)
  • US
  • Canada
• Europe (Disease Indication, Drug Class, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Indication, Drug Class, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Indication, Drug Class, Distribution)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Indication, Drug Class, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca (Farxiga)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Jardiance)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Travere Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Calliditas Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chinook Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reata Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akebia Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proteovant Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Goldfinch Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omeros Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations